Home Supplements That Start With G Gamma-linolenic acid: What It Does, Evidence for Skin and Joint Health, Dosage...

Gamma-linolenic acid: What It Does, Evidence for Skin and Joint Health, Dosage Ranges, and Side Effects

3

Gamma-linolenic acid (GLA) is a plant-derived omega-6 fatty acid found in borage seed, evening primrose, and black currant seed oils. In the body, GLA converts to dihomo-gamma-linolenic acid (DGLA), a precursor to anti-inflammatory eicosanoids such as prostaglandin E1. That biology explains why GLA is marketed for skin comfort, joint health, and women’s health concerns. The real picture is more nuanced. Evidence is strongest for specific situations—such as certain trials in rheumatoid arthritis and diabetic neuropathy—while high-quality reviews show no benefit for atopic dermatitis. Quality and safety also vary by source; for example, unpurified borage can carry pyrrolizidine alkaloids that harm the liver. This guide translates the science into practical steps: what GLA does, where it helps (and where it doesn’t), how to choose and use it, sensible dosage ranges, interactions to avoid, and who should steer clear.

Quick Summary

  • May support joint comfort and nerve symptoms in select studies; no proven benefit for eczema.
  • Do not use borage products unless labeled PA-free; avoid combining GLA with blood-thinners without medical advice.
  • Typical supplemental intake: 240–600 mg GLA/day; higher intakes (1,400–2,800 mg/day) were used in some rheumatoid arthritis trials.
  • Avoid during pregnancy and breastfeeding unless your clinician agrees; avoid if you have liver disease or a history of substance misuse.

Table of Contents

What is gamma-linolenic acid?

Gamma-linolenic acid (GLA, 18:3 n-6) is an omega-6 polyunsaturated fatty acid present in small amounts in human diets but concentrated in a few seed oils: borage seed oil (typically the highest), black currant seed oil (intermediate), and evening primrose oil (lower, but widely available). After ingestion, enzymes rapidly elongate GLA to dihomo-gamma-linolenic acid (DGLA, 20:3 n-6). DGLA then competes with arachidonic acid (AA) for cyclooxygenase and lipoxygenase pathways. When DGLA “wins,” the body produces more series-1 prostaglandins and thromboxanes and fewer AA-derived leukotrienes—biochemicals generally associated with calmer inflammatory signaling and vasodilation.

Two features make GLA different from “generic omega-6” intake. First, most omega-6 in modern diets is linoleic acid (LA), which can become either DGLA (anti-inflammatory lean) or AA (potentially pro-inflammatory), depending on enzyme traffic and background omega-3 status. Second, supplying preformed GLA nudges the pathway toward DGLA, which may be useful when delta-6-desaturase activity is sluggish (aging, diabetes, alcohol overuse, certain genetic variants) or when a person needs targeted support for specific tissues such as skin and nerves.

GLA is not a magic anti-inflammatory switch. It can also increase AA levels in some people, especially at higher intakes and in the absence of sufficient long-chain omega-3s (EPA/DHA). That’s why several clinical protocols combine GLA with fish-oil–derived EPA/DHA to tilt the balance toward DGLA-mediated effects while discouraging AA accumulation.

You’ll encounter GLA in three main forms on labels:

  • Evening primrose oil (EPO), often 8–10% GLA by weight.
  • Borage seed oil, often 18–24% GLA (highest potency per softgel).
  • Black currant seed oil, often 15–20% GLA and naturally containing some ALA and SDA (omega-3 precursors).

The “mg GLA” on a facts panel matters more than the total oil. A 1,000 mg evening primrose capsule at 10% GLA delivers ~100 mg GLA, while a 1,000 mg borage capsule at 20% GLA delivers ~200 mg GLA. Choosing by verified GLA content simplifies planning and reduces pill burden.

Finally, quality matters. Borage belongs to a plant family that can produce pyrrolizidine alkaloids (PAs). These compounds are hepatotoxic. Reputable borage oils are explicitly purified and labeled “PA-free” and tested to tight limits. If that language is missing, choose a different product.

Back to top ↑

Does it work? Benefits you can expect

The strongest clinical support for GLA is condition-specific—not universal.

Skin health and eczema
A long-standing hypothesis proposed that some people with atopic dermatitis (eczema) have sluggish conversion of linoleic acid to GLA and DGLA, leading to impaired skin barrier lipids. Supplementing GLA was supposed to fix that. However, a major systematic review pooling dozens of randomized trials found no meaningful benefit of oral evening primrose or borage oil on physician- or patient-rated eczema outcomes compared with placebo. That doesn’t mean nobody ever feels better—placebo responses and individual variability exist—but it does mean expectations should be modest. For general skin dryness or comfort, people sometimes report softer skin on modest GLA intake, yet robust, reproducible effects for eczema are not demonstrated.

Nerve support in diabetic neuropathy
Multiple randomized trials have tested GLA in peripheral neuropathy. A 1-year, multicenter, double-blind trial using 480 mg GLA/day showed statistically significant improvements across nerve conduction and symptom metrics versus placebo, with greater benefit among participants with better glycemic control. More recent work compared GLA with alpha-lipoic acid for 12 weeks in painful diabetic neuropathy and suggested similar symptomatic improvements in a noninferiority design. These data point to plausible, clinically relevant effects for some patients when GLA is dosed adequately and glucose control is addressed in parallel.

Joint comfort and rheumatoid arthritis (RA)
GLA and DGLA-derived mediators may modulate synovial inflammation. Several controlled studies—including a rigorous trial using high-dose GLA (2.8 g/day)—reported improvements in tender/swollen joint counts and pain measures versus placebo. Benefits are not universal, and trial designs vary (some combine GLA with omega-3s). Still, the pattern suggests that adequately dosed GLA can play an adjunct role for some people with inflammatory arthritis, typically alongside standard care. Notably, the effective intakes in positive RA trials are much higher than those found in typical single-softgel products.

Women’s health symptoms
Evening primrose oil is widely used for cyclical breast discomfort and premenstrual symptoms. Findings are mixed. Some small trials favor EPO; others do not. If tried, reasonable expectations and a defined trial period (for example, two to three cycles) are prudent.

Cardiometabolic and general inflammation
Mechanistically, DGLA-derived prostaglandin E1 has vasodilatory and antiplatelet properties. Human trials specifically linking GLA to hard cardiometabolic outcomes remain limited. In practice, a combined strategy (dietary pattern plus omega-3s, with optional GLA) is more evidence-aligned than GLA alone.

Bottom line

  • Most consistent signal: select trials in diabetic neuropathy and rheumatoid arthritis when dosed adequately.
  • Negative or neutral: high-quality eczema evidence does not support oral GLA for atopic dermatitis.
  • Uncertain or mixed: PMS/mastalgia and general inflammatory complaints.
  • Practical implication: consider GLA as a targeted adjunct, not a cure-all, and match the dose and trial length to the specific goal.

Back to top ↑

How to take GLA the right way

Choose by verified GLA milligrams, not just “oil milligrams.” Check the Supplement Facts panel: it should list both total oil and GLA per serving. Multiply by the number of softgels you plan to take to reach a daily target.

Pick a source that fits your needs and risk profile

  • Evening primrose oil (8–10% GLA): gentler potency per capsule; widely available for general wellness trials.
  • Black currant seed oil (15–20% GLA): intermediate potency and includes other fatty acids (ALA, SDA).
  • Borage seed oil (18–24% GLA): highest potency per capsule; must be labeled PA-free with validated testing to avoid pyrrolizidine alkaloids. Favor brands that disclose PA testing methods or carry third-party certifications.

Time and with-food guidance
Take GLA with meals to reduce burping and improve absorption. Fat-containing meals aid uptake. Split dosing (for example, morning and evening) can smooth tolerance at higher intakes.

Combine with omega-3s when helpful
To steer GLA metabolism toward DGLA rather than AA, many protocols add EPA/DHA (for example, 1–2 g/day combined EPA+DHA). That combination has biochemical plausibility and appears in several arthritis studies. If you already take fish oil, you may not need extra; simply maintain your usual EPA/DHA intake when starting GLA.

Trial length and expectations

  • Skin comfort and general wellness: allow 6–8 weeks to judge changes in dryness or subjective comfort.
  • Neuropathy: trials used 12–52 weeks at higher doses; discuss oversight and realistic goals with your clinician.
  • Joint symptoms: arthritis studies often used 8–24 weeks before formal assessment, with higher dosing.

Quality markers to look for

  • Explicit PA-free statement for borage.
  • Per-batch testing and certificates of analysis on request.
  • Oxidation control: recent production date, dark or opaque bottles, nitrogen-flushed packaging where possible.
  • Additives: minimal flavorings; mixed tocopherols as antioxidants are common and acceptable.

When to involve your clinician

  • You take anticoagulants, antiplatelet agents, or NSAIDs regularly.
  • You have liver disease, epilepsy, or are pregnant or breastfeeding.
  • You plan high-dose intake (>1,000 mg GLA/day) or a long trial (>3 months).
  • You live with diabetes and are considering GLA for neuropathy—glucose management and medication review are essential.

Back to top ↑

How much GLA per day?

Your goal and the formulation you choose determine the daily GLA target. The ranges below reflect common practice patterns and doses used in published trials. Always individualize with your clinician, especially if you take other medications.

Everyday wellness and skin comfort

  • Typical range: 240–600 mg GLA/day, taken with meals.
  • Source examples:
  • 2–6 softgels/day of evening primrose oil at 10% GLA (each ~100 mg GLA).
  • 1–3 softgels/day of borage at 20% GLA (each ~200 mg GLA), PA-free only.
  • 2–4 softgels/day of black currant seed oil at ~16% GLA (each ~160 mg GLA).

Atopic dermatitis (eczema)

  • Evidence summary: high-quality meta-analysis shows no benefit of oral evening primrose or borage oil versus placebo for eczema symptoms. If tried for general skin comfort despite this, stay within the everyday range above and reassess after 8 weeks.

Diabetic peripheral neuropathy (with medical oversight)

  • Studied dose: 480 mg GLA/day for 12–52 weeks in randomized trials.
  • Important: better outcomes tracked with good glycemic control. Discuss with your diabetes care team before starting.

Rheumatoid arthritis (adjunct to standard care)

  • Studied doses: 1,400–2,800 mg GLA/day in several trials, sometimes combined with omega-3s.
  • Practical translation: this is a therapeutic intake requiring many capsules unless using high-GLA borage; it should be coordinated with your rheumatology team and monitored for tolerance and interactions.

Women’s health symptoms (PMS, cyclical breast discomfort)

  • Common practice: 240–400 mg GLA/day for a 2–3 cycle trial, then reassess.
  • Evidence: mixed; set conservative expectations.

Dosing tips

  • Start low for 1–2 weeks to check tolerance, then step up toward the target.
  • Consider pairing with 1–2 g/day EPA+DHA if you use higher GLA intakes or have an inflammatory condition.
  • If you miss a dose, simply resume at the next meal—no “catch-up” dosing.

Upper limits and duration

  • Human studies report good tolerance up to approximately 2.8 g GLA/day under monitoring, though this is far above everyday use. Long-term daily intake at 240–600 mg GLA is common in supplements. If you plan more than 3 months of continuous use, revisit the plan with your clinician and check that all medications and lab values (for example, liver enzymes when using borage products) remain appropriate.

Back to top ↑

Common mistakes and interactions to avoid

Focusing on “oil mg,” not “GLA mg.”
Two products can both say “1,000 mg softgels” and differ two-fold in actual GLA content. Always calculate mg of GLA per day. That’s the biologically active fraction you’re targeting.

Using borage oil without PA-free verification.
Pyrrolizidine alkaloids (PAs) can contaminate borage and related botanicals and are toxic to the liver. Only choose borage oils explicitly labeled PA-free and favor brands that publish third-party testing. If you cannot verify PA status, choose evening primrose or black currant seed oil instead.

Expecting GLA to treat eczema.
Despite the plausible mechanism, trials do not support oral GLA for atopic dermatitis. Manage expectations and consider evidence-based skin care strategies (emollients, trigger avoidance, clinician-directed therapies).

Skipping omega-3s at higher GLA intakes.
Because GLA can raise arachidonic acid in some people, pairing with EPA/DHA helps tilt lipid mediators toward DGLA-dominant, calmer profiles. If you’re already taking fish oil, you may be covered; if not, discuss whether a combined approach fits your goals.

Combining with medications that increase bleeding risk.
GLA-derived prostaglandin E1 has antiplatelet effects. Use caution and medical oversight if you take warfarin, DOACs, antiplatelets (for example, clopidogrel), or high-dose NSAIDs. Watch for easy bruising, nosebleeds, or gum bleeding and report them promptly.

Using during pregnancy or with liver disease without guidance.
Avoid GLA supplements, especially borage-derived products, during pregnancy and breastfeeding unless your clinician recommends otherwise. People with liver disease should avoid borage oils altogether and discuss other GLA sources carefully.

Assuming faster is better.
Higher doses are not automatically more effective and may increase side effects (GI upset, loose stools, reflux). Stepwise titration with a clear stop-date for reassessment works better than open-ended escalation.

Back to top ↑

Who should avoid GLA and when to stop

Avoid GLA or use only with specialist input if any of the following apply:

  • Pregnancy or breastfeeding. Safety data are limited; borage-derived products pose extra concern due to potential PA contamination even when labeled PA-free.
  • Liver disease or abnormal liver tests. Choose non-borage sources with caution or avoid entirely; discuss with your clinician first.
  • Bleeding disorders or anticoagulant/antiplatelet therapy. Potential additive effects on bleeding risk call for individualized guidance and monitoring.
  • Epilepsy or a history of seizures. Some authorities advise caution with evening primrose oil in people with seizure disorders; discuss case-by-case.
  • Upcoming surgery. Stop GLA 1–2 weeks before scheduled procedures to minimize bleeding risk unless your surgeon advises otherwise.
  • Allergy to the source plant. Rare, but avoid if you’ve reacted to borage, evening primrose, black currant, or related botanicals.

Stop and seek medical advice if you notice:

  • Unusual bruising or bleeding; dark stools; persistent nosebleeds.
  • Right-upper-quadrant abdominal pain, yellowing of skin/eyes, or dark urine (possible liver issues).
  • New neurological symptoms (for example, seizures).
  • Worsening rash or unexpected allergic reactions.

Children and adolescents
Routine GLA supplementation for children is not established. If you’re considering GLA for a child (for example, for skin comfort), coordinate with a pediatric clinician and prioritize non-pharmacologic skin-care measures first.

Practical alternatives and complements

  • Dietary pattern: whole-food, plant-forward diets with fish twice weekly provide EPA/DHA and diverse polyphenols that modulate inflammation.
  • Topical care for eczema: fragrance-free, ceramide-rich moisturizers; lukewarm bathing; trigger management.
  • Joint health: physical therapy, strength training, weight management, and guideline-directed medications as indicated.
  • Nerve support: glucose optimization, foot care, and prescribed neuropathy treatments when needed.

Back to top ↑

Evidence snapshot and what remains uncertain

What’s solid

  • Eczema: A comprehensive Cochrane meta-analysis concluded that oral evening primrose and borage oil do not improve eczema symptoms versus placebo, across patient- and physician-reported outcomes. This weighs heavily against recommending GLA specifically for atopic dermatitis.
  • Diabetic neuropathy: A 1-year, multicenter, randomized trial using 480 mg/day GLA reported statistically significant improvements in multiple neuropathy measures. A more recent 12-week noninferiority trial suggested GLA performs comparably to alpha-lipoic acid for painful neuropathy, a useful benchmark.
  • Rheumatoid arthritis: Several trials—including one using 2.8 g/day GLA—demonstrated improvements in clinical signs and symptoms. Reviews also note potential synergy when GLA is co-supplemented with omega-3s. These data support GLA as a potential adjunct, not a replacement for disease-modifying therapy.

What’s mixed or limited

  • PMS and cyclical mastalgia: Study results vary; some show benefit, others do not. If used, keep doses modest and reassess quickly.
  • Cardiometabolic markers: Mechanistic plausibility exists via DGLA-derived eicosanoids, but robust outcome data remain sparse.
  • Long-term safety at high doses: Clinical trials report good tolerance under monitoring, yet routine use at multi-gram GLA intakes outside studies isn’t well characterized.

What to watch

  • Quality standards for borage oils: Regulatory attention to pyrrolizidine alkaloids has sharpened, with updated limits and surveillance in the EU. Choose PA-free products from manufacturers that disclose analytical testing.
  • Personal biology: Variants in fatty-acid desaturase genes, background diet (especially omega-3 intake), alcohol use, and metabolic health likely influence individual responses to GLA. That may explain why some people experience clear benefits and others do not at the same dose.

Decision guide in one line
If your goal is eczema control, GLA is unlikely to help. If your goal is nerve or joint comfort, a time-boxed, properly dosed trial—ideally with clinician input and paired with omega-3s—can be reasonable, provided interactions and quality concerns are addressed.

Back to top ↑

References

Medical Disclaimer

This content is educational and does not replace advice from your healthcare professional. Do not use GLA to diagnose, treat, or manage any condition without medical guidance. People who are pregnant or breastfeeding, have liver disease, bleeding disorders, epilepsy, or take anticoagulants or antiplatelet medications should consult a clinician before using GLA. If you experience unusual bruising, bleeding, jaundice, severe abdominal pain, or neurological symptoms, stop the supplement and seek medical care.

If you found this guide helpful, please consider sharing it on Facebook, X (formerly Twitter), or your preferred platform, and follow us for future evidence-based health articles. Your support helps us continue creating high-quality content.

RELATED ARTICLESMORE FROM AUTHOR